Despite promising results for current immunotherapy with anti-PD-1 immune checkpoint inhibitors for selected patients with persistent, recurrent, or metastatic head and neck squamous cell carcinoma, high rates of treatment failure still occur, mainly through the ability of cancer cells to evade the immune system. This evidence concerns the gene PDCD1 and cancer.